Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observation Monocentric Study to Analyse the Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients

NCT04902690 is registered in ClinicalTrials.gov with IRCCS National Neurological Institute "C. Mondino" Foundation as lead sponsor.

NCT NCT04902690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04902690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observation Monocentric Study to Analyse the Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients
Lead sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Phase
Observational
Overall status
Unknown status
Start date
May 31, 2021
Completion date
July 31, 2024
Enrollment
21 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis relapse